Navigation Links
ImmBio Wins Funding from UK Government-Backed Biomedical Catalyst to Develop Multi-Strain Pneumococcal Vaccine
Date:3/12/2013

CAMBRIDGE, England, March 12, 2013 /PRNewswire/ --

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.  This new grant follows the award of approximately £1 million ($1.5 million) at the end of 2012 by the Biomedical Catalyst, to support the development of ImmBio's novel meningococcal B vaccine, MenBioVax™.  The Biomedical Catalyst is a programme of public funding managed jointly by the UK's innovation agency, the Technology Strategy Board, and the Medical Research Council, which has to date awarded nearly £96 million to 115 projects to support the accelerated development of innovative solutions to healthcare challenges.

ImmBio's vaccine candidates are based on its proprietary ImmBioVax™ technology platform.  This uses novel cell-culture production processes to stress the target bacterial pathogen, mimicking the natural immune response to infection.  This innovative approach generates vaccines that incorporate multi-protein complexes, offering potential broad-based protection against a wide range of pathogen strains without the need for adjuvants or other immune stimulators.  

"ImmBio is delighted to receive funding from the UK's innovation agency and Medical Research Council to progress the development of our novel vaccines", said Graham Clarke , CEO of ImmBio.  "Successfully winning funding in both the first and second Biomedical Catalyst investment rounds represents a major vote of confidence in our ImmBioVax™ vaccine technology.  This most recent award recognises the need for effective new vaccines against invasive pneumococcal disease, and the potential of our technology to protect against a wide range of disease-causing strains."

About pneumococcal disease

Invasive pneumococcal disease is caused by Streptococcus pneumoniae bacteria.  The infection can be devastating, particuarly in developing countries, and is responsible for greater infant mortality than tuberculosis, HIV and malaria combined.  Between 5-10% of adults and 20-40% of children carry the bacteria, and over 90 different strains have been identified to date.  These evolve continually leading to the emergence of new strains, and antibiotic resistance is a significant and growing problem.  Current vaccines cover only a limited number of existing strains and may not be effective against those that emerge in future.  In addition, existing vaccines can be expensive for routine use in developing countries.

About ImmBio

ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary novel ImmBioVax™ technology.  During vaccine production, ImmBioVax™ mimics the normal immune response to a pathogen.  This process produces vaccines containing multi-protein complexes that are designed to elicit broad-based priming of the immune system to block subsequent infection by multiple strains of the pathogen.  ImmBio is developing vaccines against a number of diseases, including invasive meningococcal disease, tuberculosis and invasive pneumococcal disease.

About the Biomedical Catalyst

The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a programme of public funding designed to deliver growth to the UK life sciences sector.  Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.  The programme is open to UK academics and SMEs and seeks to support those opportunities that demonstrate the highest scientific and commercial potential, irrespective of medical area.  For further information please visit: http://www.innovateuk.org/content/competition/biomedical-catalyst.ashx.

Contacts
Graham Clarke
CEO
ImmBio
Tel: +44(0)1223-496117
http://www.immbio.com

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241


'/>"/>
SOURCE ImmBio
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Independa Closes Convertible Note Funding at $2.35 Million
2. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Igenica Closes $33 Million in Series C Funding
5. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
6. BONESUPPORT Closes Second Tranche of Funding
7. DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
8. RD Legal Funding Provides Immediate Settlement Financing to Growing Number of Yaz and Yasmin Plaintiffs
9. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
10. Prosum Kicks Off Crowd Funding for Cancer Research
11. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - ... service medical device development firm, announced today that it ... Toronto -based medical device industrial design and productization ... companies throughout North America with ... device talent spanning the design, engineering, regulatory, and manufacturing ...
(Date:3/28/2017)... and TEL AVIV, Israel , March 28, 2017 ... Israel . This new business entity, Emosis Ltd, ... dedicated to research and development of novel assays complementing the mother ... when relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... , ... Hamlin Dental Group, multi-location dental office in North Hollywood , ... are safe and effective options, and can be used alone or in conjunction with ... of care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as ...
(Date:3/29/2017)... ... ... has helped over 1.5 million SharePoint users learn the content management system faster and ... for SharePoint was at the farm level. Enterprises using SharePoint Online in Office 365 ... recently released a modified version of the Help System, VisualSP for Site Collections, which ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is expanding ... extensive knowledge of appraisals, property values, ad valorem taxation, and government policy to ... for more than 40 years. , “Ruel is a great addition to the ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... Wallingford, CT (PRWEB) , ... March 28, 2017 ... ... hemostatic devices, announces today that the University of Pittsburgh Medical Center (UPMC) will ... Central and Western Pennsylvania. , The program, developed in association with efforts by ...
Breaking Medicine News(10 mins):